Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
03/2005
03/31/2005US20050069866 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
03/31/2005US20050069865 Synthetic hcv envelope proteins and their use for vaccination
03/31/2005US20050069589 cross-linkable protein in the form of a solution or suspension; cross-linking agent solution includes an aldehyde and an amino acid containing species reactive with the aldehyde
03/31/2005US20050069569 Osteocalcin; enzyme inhibitors; promote bone, teeth growth; administering Dna gene
03/31/2005US20050069561 vaccine against Newcastle Disease contains one or more mutant immunogens of the NDW strain that lack the antigenic binding site on the F glycoprotein which is recognized by the monoclonal antibody mAb 54.
03/31/2005US20050069560 Immunosuppressant prodigiosin; pure culture; transplatation of organs, tissues
03/31/2005US20050069559 Lawsonia intracellularis vaccine
03/31/2005US20050069558 Machine readable media embedded in three-dimensional matrix; severe acute respiaroty system; crystal structure polypeptide; detection; drug design
03/31/2005US20050069557 A protein neuroglobin derived from neuronal tissue; binging, storage oxygen; therapy for central nervous system disorders
03/31/2005US20050069556 Serology display library; analyzing autologous tumor antigen; drug design; antitumor vaccine containing antigen
03/31/2005US20050069555 Vaccine adjuvants; hepatitis c virus; modulation immunology response
03/31/2005US20050069547 Binding protein; therapy for bone tumors
03/31/2005US20050069546 Educated NKT cells and their uses in the treatment of immune-related disorders
03/31/2005US20050069543 Antibody mixture; immunosuppressant ; antitumor agents
03/31/2005US20050069541 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
03/31/2005US20050069539 Anticancer agents; genetic engineering; monoclonal antibodies
03/31/2005US20050069537 Stimulants of survival of cells; binding of cellular adhesion molecular; prevent apoptosis
03/31/2005US20050069536 Contacting male ejaculate, prior to contact with a female egg, with an effective anti-fertility amount of a pharmaceutical composition, which comprises an antibody that binds a surface exposed epitope of SP22, and a pharmaceutically acceptable carrier
03/31/2005US20050069535 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
03/31/2005US20050069521 Enhancing the circulating half-life of interleukin-2 proteins
03/31/2005US20050069491 Dna sequences encoding detectable cytotoxic protein generating signal; tumor imaging; gene expression
03/31/2005CA2540138A1 Recombinant antibody against human insulin-like growth factor
03/31/2005CA2540133A1 Drugs for treating cancer
03/31/2005CA2540129A1 Pharmaceutical delivery system
03/31/2005CA2540103A1 Selective inhibition of nf-kappab activation by peptides designed to disrupt nemo oligomerization
03/31/2005CA2539789A1 Peptide originating in hepatitis c virus
03/31/2005CA2539562A1 Methods, kits, and compositions for the development and use of monoclonal antibodies specific to antigens of low immunogenicity
03/31/2005CA2539437A1 Peptide that binds to a broadly neutralizing anti-hiv antibody-structure of 4e10 fab fragment complex, uses thereof, compositions therefrom
03/31/2005CA2539325A1 Consensus/ancestral immunogens
03/31/2005CA2539322A1 Kid3 and kid3 antibodies that bind thereto
03/31/2005CA2539270A1 Immunogen
03/31/2005CA2539116A1 Cripto antagonism of activin and tgf-b signaling
03/31/2005CA2539074A1 Campylobacter polypeptides and methods of use
03/31/2005CA2539061A1 Use of an antagonist of il-6 for treating il-6-mediated diseases
03/31/2005CA2539021A1 Combination approaches for generating immune responses
03/31/2005CA2538887A1 Measles subunit vaccine
03/31/2005CA2538840A1 Dna vaccine compositions and methods of use
03/31/2005CA2538794A1 Vaccine for treatment and prevention of herpes simplex virus infection
03/31/2005CA2538284A1 Modulators of p-selectin glycoprotein ligand 1
03/31/2005CA2538252A1 4'-thionucleosides and oligomeric compounds
03/31/2005CA2537742A1 Immunogenic compositions for streptococcus agalactiae
03/31/2005CA2537725A1 Method for vaccination of poultry by bacteriophage lysate
03/31/2005CA2535645A1 Therapeutic immunization of hiv-infected individuals
03/31/2005CA2534959A1 Antibodies with altered effector functions
03/31/2005CA2526862A1 Methods of diagnosing, prognosing and treating breast cancer
03/31/2005CA2526834A1 Recombinant influenza vectors with a polii promoter and ribozymes
03/31/2005CA2523657A1 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
03/30/2005EP1519192A2 HIV Protease inhibitor conjugates and antibodies useful in ummunoassay
03/30/2005EP1518932A1 Modified vaccinia virus Ankara (MVA) mutant and use thereof
03/30/2005EP1518927A2 Optimization of immunomodulatory properties of genetic vaccines
03/30/2005EP1518864A2 Antibody against rhesus D
03/30/2005EP1518558A2 Vaccine against infection with Actinobacillus pleuropneumoniae comprising purified ApxIV toxin
03/30/2005EP1517995A2 Compositions and methods for the detection of human t cell receptor variable family gene expression
03/30/2005EP1517989A2 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
03/30/2005EP1517987A2 Cotton rat lung cells for virus culture
03/30/2005EP1517923A2 Compositions and methods for inhibiting microbial adhesion
03/30/2005EP1517922A2 Preparation based on an antibody directed against a tumor-associated glycosylation such as lewis structures
03/30/2005EP1517912A2 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
03/30/2005EP1517704A1 Use of antibodies against flt-1 for the treatment of osteoporosis
03/30/2005EP1517703A1 Placental growth factor as a target for the treatment of osteoporosis
03/30/2005EP1517702A2 IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
03/30/2005EP1517701A2 Lewis y epitope-containing mucin fusion polypeptide vaccines, compositions and methods of use thereof
03/30/2005EP1517700A2 Mucin fusion polypeptide vaccines, compositions and methods of use thereof
03/30/2005EP1517695A2 Osteopontin, oligodendrocytes and myelination
03/30/2005EP1517692A1 Method and agent for the prevention, inhibition and treatment of sepsis
03/30/2005EP1517606A2 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
03/30/2005EP1392341B1 Pharmaceutical composition containing a stabilised mrna which is optimised for translation in the coding regions thereof
03/30/2005EP1282448B1 Heterobifunctional cross-linking agent conjugate substituted by an immunomodulator and cell recognition unit
03/30/2005EP1224298B1 Fibrinolytically active polypeptide
03/30/2005EP1203088B1 Conditionally controlled, attenuated hiv vaccine
03/30/2005EP1135414B1 Allo and auto-reactive t-cell epitopes
03/30/2005EP1076561B1 Combination therapy for the treatment of tumors
03/30/2005EP1001978B1 Angiotensin derivatives
03/30/2005EP0929232B1 Method of improving the growth or the efficiency of feed conversion of an animal and compositions for use therein
03/30/2005CN1602427A Inhibition of tristetraproline for protection of the heart from cardiac injuries
03/30/2005CN1602425A Therapeutic and diagnostic uses of antibody specificity profiles
03/30/2005CN1602317A Angiopoietin-2 specific binding agents
03/30/2005CN1602316A Flavivirus NS1 subunit vaccine
03/30/2005CN1602216A Microprojection array immunization patch and method
03/30/2005CN1602207A Methods for inhibiting ocular processes
03/30/2005CN1602205A Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
03/30/2005CN1602204A Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies
03/30/2005CN1602203A Use of gp130 activators in diabetic neuropathy
03/30/2005CN1602199A Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
03/30/2005CN1600856A Method for constructing hybridoma cell line of heterogeneity of seereting human monoclonal antibody for anti hepatitis B
03/30/2005CN1600852A Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup B
03/30/2005CN1600849A Bacilluscoli 0157 gene deficiency bacterin of intestinal hemorrhage
03/30/2005CN1600791A SARS antigen peptide
03/30/2005CN1600506A Mini folding knife having locking means
03/30/2005CN1600369A Method for preparing targeting preparation of human monoclonal antibody crosslinking interferon for anti hepatitis b virus
03/30/2005CN1600368A Attenuated live vaccine of eel vibrio
03/30/2005CN1195056C Recombined virus for specific proliferation and high efficiency expression of anti-cancer gene in tumor cells and its constitution method
03/30/2005CN1194986C Type-c hepatitis virus high-variation-zone 1 synthesized peptide and use thereof
03/30/2005CN1194759C Tetrodotoxin conjugate and medicine composition having same
03/30/2005CN1194758C Vaginal lactobacillus medicant
03/30/2005CN1194670C Methods and compositions for detection and diagnosis of in fectious diseases
03/29/2005US6872814 Chlamydia antigens and corresponding DNA fragments and uses thereof
03/29/2005US6872750 Modulating angiogenesis
03/29/2005US6872568 Death domain containing receptor 5 antibodies
03/29/2005US6872559 Diagnosis of urogenital disorders
1 ... 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 ... 1823